1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Diabetes DTC Ads Stand Out For Off-Label Promotion, Study Finds

 
• By Jessica Merrill

Drugs like Victoza, Farxiga, Jardiance, Trulicity, and Invokana were called out for promoting weight loss and blood pressure reduction by Yale University researchers in a new study published in the Journal of General Internal Medicine.

Diabetes drugs are the biggest culprit when it comes to off-label claims in direct-to-consumer TV advertising, according to a study by Yale University researchers published in the Journal of General Internal Medicine Feb. 26.

Of 97 unique TV ads reviewed in the study, the 13 with misleading off-label claims were all for diabetes drugs, according to the researchers. Those ads suggested potential benefits for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.